The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. (May 2021)
- Record Type:
- Journal Article
- Title:
- The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. (May 2021)
- Main Title:
- The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19
- Authors:
- Campos-Varela, Isabel
Villagrasa, Ares
Simon-Talero, Macarena
Riveiro-Barciela, Mar
Ventura-Cots, Meritxell
Aguilera-Castro, Lara
Alvarez-Lopez, Patricia
Nordahl, Emilie A
Anton, Adrian
Bañares, Juan
Barber, Claudia
Barreira-Diaz, Ana
Biagetti, Betina
Camps-Relats, Laura
Ciudin, Andrea
Cocera, Raul
Dopazo, Cristina
Fernandez, Andrea
Jimenez, Cesar
Jimenez, Maria M
Jofra, Mariona
Gil, Clara
Gomez-Gavara, Concepción
Guanozzi, Danila
Guevara, Jorge A
Lobo, Beatriz
Malagelada, Carolina
Martinez-Camprecios, Joan
Mayorga, Luis
Miret, Enric
Pando, Elizabeth
Pérez-Lopez, Ana
Pigrau, Marc
Prio, Alba
Rivera-Esteban, Jesus M
Romero, Alba
Tasayco, Stephanie
Vidal-Gonzalez, Judit
Vidal, Laura
Minguez, Beatriz
Augustin, Salvador
Genesca, Joan
… (more) - Abstract:
- Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death thanLiver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years. … (more)
- Is Part Of:
- Therapeutic advances in gastroenterology. Volume 14(2021)
- Journal:
- Therapeutic advances in gastroenterology
- Issue:
- Volume 14(2021)
- Issue Display:
- Volume 14, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 14
- Issue:
- 2021
- Issue Sort Value:
- 2021-0014-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-05
- Subjects:
- ALT -- AST -- controlled attenuation parameter -- CAP -- liver injury
Gastroenterology -- Periodicals
Digestive organs -- Diseases -- Treatment -- Periodicals
Gastrointestinal system -- Diseases -- Treatment -- Periodicals
Liver -- Diseases -- Treatment -- Periodicals
Pharmacology -- Periodicals
Gastroenterology -- Periodicals
Gastrointestinal Diseases -- therapy -- Periodicals
Liver Diseases -- therapy -- Periodicals
Pharmacology -- Periodicals
Gastroentérologie -- Périodiques
Appareil digestif -- Maladies -- Traitement -- Périodiques
Tractus gastro-intestinal -- Maladies -- Traitement -- Périodiques
Hépatologie -- Périodiques
Foie -- Maladies -- Périodiques
Pharmacologie -- Périodiques
616.3005 - Journal URLs:
- http://rave.ohiolink.edu/ejournals/issn/1756283x/ ↗
http://tag.sagepub.com/ ↗
http://www.uk.sagepub.com/home.nav ↗
http://www.tag.sagepub.com/ ↗ - DOI:
- 10.1177/17562848211016567 ↗
- Languages:
- English
- ISSNs:
- 1756-283X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18675.xml